LYRA
Lyra Therapeutics Inc
NASDAQ: LYRA · HEALTHCARE · BIOTECHNOLOGY
$0.71
+0.00% today
Updated 2026-04-30
Market cap
$870050.00
P/E ratio
—
P/S ratio
1.45x
EPS (TTM)
$-22.90
Dividend yield
—
52W range
$0 – $34
Volume
0.1M
Lyra Therapeutics Inc (LYRA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-6.64M | $-13.75M | $-21.14M | $-25.82M | $-43.38M | $-63.30M | $-70.01M |
| Capital expenditures | $37000.00 | $211000.00 | $1.77M | $3.38M | $164000.00 | $1.05M | $2.34M |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $406000.00 | $244000.00 | $1.81M | $2.77M | $5.45M | $5.89M | $6.72M |
| Free cash flow | $-6.68M | $-13.96M | $-22.92M | $-29.20M | $-43.55M | $-64.35M | $-72.35M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $64.78M | — | — | — | — |